Last reviewed · How we verify
MK-1293
MK-1293 is a glucagon receptor antagonist.
MK-1293 is a glucagon receptor antagonist. Used for Type 2 diabetes.
At a glance
| Generic name | MK-1293 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Glucagon receptor antagonist |
| Target | Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glucagon receptor antagonists work by blocking the action of glucagon, a hormone that raises blood glucose levels. By inhibiting glucagon, MK-1293 aims to lower blood glucose levels in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006) (PHASE3)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005) (PHASE1)
- A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-1293 CI brief — competitive landscape report
- MK-1293 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI